Published in Prog Neuropsychopharmacol on January 01, 1981
BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation. J Neural Transm (Vienna) (2007) 1.31
A study of psycho-behavioral patterns in patients emerging from general anesthesia using sevoflurane, propofol and their combination in early, intermediate and late post-operative period: A randomized controlled trial. Anesth Essays Res (2015) 0.75
Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet (2000) 3.05
Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol (1998) 1.51
Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry (1994) 1.48
Thyrotropin releasing hormone potentiates the effects of imipramine on brain serotonergic system. Brain Res Bull (1981) 1.39
Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry (1987) 1.06
Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry (1999) 1.03
Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiatry Neurosci (1995) 0.97
Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord (1996) 0.97
A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis. J Clin Psychiatry (1982) 0.92
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry (1999) 0.90
Benzodiazepine withdrawal. Can J Psychiatry (1981) 0.89
Evidence for the role of brain norepinephrine and dopamine in "rebound" phenomenon seen during withdrawal after repeated exposure to benzodiazepines. J Psychiatr Res (1977) 0.88
Koro in a French Canadian. Can Psychiatr Assoc J (1972) 0.88
Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Psychiatry Res (1997) 0.87
Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res (1999) 0.86
A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci (1995) 0.86
Are all benzodiazepines clinically equivalent? Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.86
Gas--liquid chromatographic determination of pipotiazine in plasma of psychiatric patients. J Chromatogr (1981) 0.85
Diazepam and benzoctamlne: effects on certain objective parameters of muscular spasticity. Curr Ther Res Clin Exp (1973) 0.85
Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J Psychiatry Neurosci (1997) 0.83
Computerized EEG correlates of depression and antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry (1987) 0.82
Effective treatment of mania with olanzapine: 2 case reports. J Psychiatry Neurosci (1997) 0.82
Some neurochemical correlates of "rebound" phenomenon observed during withdrawal after long-term exposure to 1, 4-benzodiazepines. Prog Neuropsychopharmacol (1978) 0.82
Reduction in suicidal ideation with SSRIs: a review of 459 depressed patients. J Psychiatry Neurosci (1993) 0.82
Fluphenazine, trifluoperazine and perphenazine in Vacutainers. Can Med Assoc J (1981) 0.82
Photophobia in depression. Am J Psychiatry (1989) 0.81
Preparatory brain potentials in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.81
[Mesoridazine therapy in neurotics-clinical trial]. Union Med Can (1972) 0.81
Pilot clinical trial of parenteral lorazepam (Temesta) in anxiety states. Psychopharmacologia (1973) 0.80
Psychophysiological correlates of sodium lactate. Psychopharmacol Bull (1984) 0.80
A controlled study of penfluridol in the treatment of chronic schizophrenia. Am J Psychiatry (1978) 0.80
Effects of lactate-induced panic attacks on brain stem auditory evoked potentials. Neuropsychobiology (1986) 0.80
Electrophysiological and behavioral correlates of psychomotor responsivity in depression. Biol Psychiatry (1987) 0.80
Auditory evoked potentials in panic disorder. J Psychiatry Neurosci (1991) 0.80
Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics. Int J Clin Pharmacol Biopharm (1975) 0.79
Ritanserin, imipramine, and placebo in the treatment of dysthymic disorder. J Clin Psychopharmacol (1993) 0.79
Diazepam potentiates the effect of neuroleptics on behavioural activity as well as dopamine and norepinephrine turnover: Do benzodiazepines have antipsychotic potency? J Neural Transm (1983) 0.79
Pimozide and the social behavior of schizophrenics. Curr Ther Res Clin Exp (1975) 0.79
SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients. Int Clin Psychopharmacol (1995) 0.78
Mianserin kinetics in depressed patients. Clin Pharmacol Ther (1983) 0.78
Neuropsychophysiological correlates of lactate-induced panic. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.78
Agitated and retarded depression. A clinical psychophysiological evaluation. Neuropsychobiology (1980) 0.78
Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.78
Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther Drug Monit (1990) 0.78
[Critical flicker fusion frequency in psychopathology and psychopharmacology. Review of the literature]. Acta Psychiatr Belg (1982) 0.78
Temporal segmentation of response speed in depression: neuro-electrophysiological approaches. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.77
Efficacy of lithium in treating mood disorder occurring after brain stem injury. Am J Psychiatry (1981) 0.77
Effects of cholinergic and GABAergic drugs on apomorphine-induced gnawing behavior in rats. Biol Psychiatry (1982) 0.77
Platelet serotonin measures in primary dysthymia. Am J Psychiatry (1994) 0.77
Thyrotropin releasing hormone: neurochemical evidence for the potentiation of imipramine effects on the metabolism and uptake of brain catecholamines. Psychopharmacology (Berl) (1980) 0.77
Panic induced by sodium lactate: electrophysiological correlates. Prog Neuropsychopharmacol (1981) 0.77
Comparison of chlormethiazole (Heminevrin) and chlordiazepoxide (Librium) in the treatment of acute alcohol withdrawal. Neuropsychobiology (1983) 0.76
Platelet 3H imipramine binding: a possible predictor of response to antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.76
Control of lithium tremor with propranolol. Can Med Assoc J (1976) 0.76
Fluvoxamine influences serotonergic system in the brain: neurochemical evidence. Neuropsychobiology (1983) 0.76
Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: focus on the serotonin hypothesis of schizophrenia. Life Sci (1981) 0.76
Phenothiazine treatment and electrocardiographic abnormalities. Can Psychiatr Assoc J (1969) 0.76
Rapid recurrence of mania following lithium withdrawal. Biol Psychiatry (1980) 0.76
Alterations in brain 5-hydroxytryptamine metabolism during the 'withdrawal' phase after chronic treatment with diazepam and bromazepam. Br J Pharmacol (1977) 0.75
Placebo: a potent but misunderstood psychotrope. J Psychiatry Neurosci (1995) 0.75
Pharmacokinetics of psychotropic drugs: what can it tell us? Prog Neuropsychopharmacol Biol Psychiatry (1982) 0.75
Lithium intoxication. Can Med Assoc J (1972) 0.75
Anxiety disorders. Part 1: Diagnosis and treatment. Can Fam Physician (1993) 0.75
Prediction of steady-state plasma levels of doxepin and imipramine from single dose levels in depressed outpatients. J Psychiatry Neurosci (1991) 0.75
Clinical-trial registration. CMAJ (1994) 0.75
Ethics and placebo. J Psychiatry Neurosci (1998) 0.75
Rapid reduction of mania by means of reserpine therapy. Am J Psychiatry (1986) 0.75
Anxiety disorders. Part 2: Pharmacotherapy with benzodiazepines. Can Fam Physician (1993) 0.75
Therapeutic monitoring of treatment with antidepressants. Psychiatr J Univ Ott (1989) 0.75
Pharmacologic management of aggressivity and self-mutilation in the mentally retarded. Psychiatr Clin North Am (1986) 0.75
Antidepressant plasma levels and clinical response in depressed patients treated with oxaprotiline and doxepin. Int Clin Psychopharmacol (1988) 0.75
[Validation of a depression threshold: the Hamilton scale]. Encephale (1982) 0.75
Toward maintenance of competence. J Psychiatry Neurosci (1993) 0.75
Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: II. Urinary metabolites of serotonin, norepinephrine, epinephrine and melatonin. J Affect Disord (1994) 0.75
Suriclone: a new anxiolytic drug. Prog Neuropsychopharmacol Biol Psychiatry (1983) 0.75
Clinical and biological correlates of panic states. Prog Neuropsychopharmacol Biol Psychiatry (1987) 0.75
[Long-acting neuroleptics. II. Pilot study of pimozide (R6238)]. Acta Neurol Psychiatr Belg (1968) 0.75
Plasma concentration of remoxipride in relation to antipsychotic effect and adverse symptoms. The Canadian Remoxipride Study Group. Acta Psychiatr Scand Suppl (1990) 0.75
New perspectives on the treatment of depression. Can J Psychiatry (1992) 0.75
Disulfiram and bipolar affective disorder: a case report. J Clin Psychopharmacol (1986) 0.75
Myalgia with the new generation antidepressants. J Clin Psychopharmacol (1986) 0.75
Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients. Ther Drug Monit (1986) 0.75
Obsessive-compulsive spectrum disorders: effective treatment with paroxetine. Can J Psychiatry (1999) 0.75
Primary early onset dysthymia, biochemical correlates of the therapeutic response to fluoxetine: I. Platelet monoamine oxidase and the dexamethasone suppression test. J Affect Disord (1994) 0.75
[Emergency treatment of agitation: droperidol (R 4749)]. Acta Neurol Psychiatr Belg (1968) 0.75
Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis. Can J Psychiatry (1985) 0.75
New concepts in the management of depression--possibilities with a non-sedative antidepressant. Acta Psychiatr Scand Suppl (1983) 0.75
Course of clinical response to antidepressants. Prog Neuropsychopharmacol Biol Psychiatry (1985) 0.75
[Effects of time variables (time-blind, time gap) on quantitative evaluation of psychopathology]. Encephale (1984) 0.75
Keratodermia: side effects of lithium. J Clin Psychopharmacol (1991) 0.75
Introduction. The multiplicity of uses of benzodiazepines. Can J Psychiatry (1993) 0.75
Nomifensine overdose with TCAs and MAOIs. J Clin Psychopharmacol (1986) 0.75
[Long-acting neuroleptics. I. Pilot study of clofluperol (R9298)]. Acta Neurol Psychiatr Belg (1968) 0.75
Erythrocyte membrane sodium-potassium and magnesium ATPase in primary affective disorder. Biol Psychiatry (1985) 0.75
Lithium as an adjunct in the treatment of major depression. Int Clin Psychopharmacol (1990) 0.75
The effect of buspirone on panic disorder: a case report. J Clin Psychopharmacol (1987) 0.75
Cholinesterases in primary affective disorders. Clin Biochem (1985) 0.75
The use of tryptophan in normal-weight bulimia. Can J Psychiatry (1986) 0.75
Zopiclone in the treatment of insomniacs of family practice. Psychiatr J Univ Ott (1985) 0.75